61 results about "Virus receptor" patented technology

The invention discloses a novel coronavirus S protein double-region subunit nano vaccine based on pyrococcus furiosus ferritin. The virus receptor binding domain (RBD) and fusion peptide (FP) are usedtogether as a double antigen, and are connected with pyrococcus furiosus ferritin (PF_Ferritin) to from a fusion protein RBD-FP-PF_Ferritin to realize antigen multimerization; and then an eukaryoticcell expression system is used for expressing, and a 24-mer nano antigen can be formed through self-assembly of PF_Ferritin. The scheme can overcome the shortcoming of insufficient immunogenicity of RBD monomers, the obtained vaccine can significantly increase the level of a neutralizing antibody against the virus of a host, and the produced antibody has the ability to strongly block the virus from invading target cells. In addition, the vaccine of the invention is simple in preparation method, is easy to purify, and is high in safety, and the vaccine can be relatively quickly applied to clinical trials.

The invention discloses a Helicobacter pylori ferritin-based novel coronavirus S protein single-region subunit nano vaccine. According to the Helicobacter pylori ferritin-based novel coronavirus S protein single-region subunit nano vaccine, a virus receptor binding domain (RBD) is used as an antigen and is connected with a helicobacter pylori polymer protein (HP _ Ferritin) to form a fusion protein RBD-HP_ Ferritin, so that antigen multimerization is realized; and expressing by using an eukaryotic cell expression system is carried out, so as to form a 24-polymer nano antigen through the self-assembly action of HP _ Ferritin. According to the scheme, the defect that RBD monomers are insufficient in immunogenicity can be overcome, the obtained vaccine can remarkably improve the level of neutralizing antibodies of a host to viruses, and the generated antibodies have the capacity of strongly preventing the viruses from invading target cells. Moreover, the vaccine is simple in preparation method, easy to purify and high in safety, and can be quickly applied to clinical tests.

Enveloped virus vectors are described which comprise a cellular virus receptor protein and which are capable of fusing with a cell which comprises a viral envelope protein to which the cellular virus receptor protein is cognate. Enveloped virus vectors comprising a plurality of cellular virus receptor proteins are also described. Methods for making the enveloped virus vectors are described, as are methods of using the enveloped virus vectors. The invention further relates to a lipoparticle comprising a membrane spanning protein, and the lipoparticle can be attached to a sensor surface. The invention relates to methods of producing and using the lipoparticle to, inter alia, assess protein binding interactions.

Enveloped virus vectors are described which comprise a cellular virus receptor protein and which are capable of fusing with a cell which comprises a viral envelope protein to which the cellular virus receptor protein is cognate. Enveloped virus vectors comprising a plurality of cellular virus receptor proteins are also described. Methods for making the enveloped virus vectors are described, as are methods of using the enveloped virus vectors. The invention further relates to a lipoparticle comprising a membrane spanning protein, and the lipoparticle can be attached to a sensor surface. The invention relates to methods of producing and using the lipoparticle to, inter alia, assess protein binding interactions.

The invention discloses a recombinant A subgroup avian leukosis virus being able to express an ALV-J envelope protein, and a construction method and a use of the virus. The virus adopts ALV-A infectious clone as a skeleton, the envelope protein of the ALV-A infectious clone is replaced by the ALV-J envelope protein, and the 3' end of the envelope protein carries luciferrase report gene, so the infectious clone of the recombinant ALV-A virus being able to express the ALV-J envelope protein is constructed. Experiments prove that the recombinant virus obtained through infectious clone rescuing has high replication ability, the tilter of the virus reaches 10<5.21> TCID50 / ml, and is 125 times that of an ALV-J original strain, and the luciferrase report gene is carried out in order to realize easy quantification. The recombinant virus can infect 293T cells for expressing chNHE1, and can be detected 8h after infection at the earliest, so the recombinant virus has high sensitivity. The a recombinant A subgroup avian leukosis virus solves the problems of low virus titer, low replication ability, and adverseness of a small amount of the virus in the early stage of virus infection to detection of traditional ALV-J viruses, and is of great significance to carry out researches related with viruses and virus receptors and anti-ALV-J antibody detection.

Disclosed is a method for screening acceptor blocker for controlling prawn virus infection, wherein the combined analytic technique for virus and prawn cell membrane protein is employed for the screening process of the virus receptor bonding blocking agent, and screening is achieved by comparing the influence of the screening article treatment to the combination of virus and prawn cell membrane protein, the three screened substances have blocking-up action to the combination of leukoplakia syndrome virus and prawn branchia cell membrane.

The invention relates to a novel cell receptor of a PRRS virus, that is, a nonmuscle myosin heavy chain II-A (NMHC II-A) protein and an inhibitor blebbistati of nonmuscle myosin II which are taken as drugs for inhibiting a PRRS virus infected cell. The invention provides a method for inhibiting the PRRS virus infected cell by purified NMHC II-A protein and synthetic polypeptide and the inhibitor blebbistati thereof. The invention further provides an antibody generated by the NMHC II-A protein and the polypeptide. The NMHC II-A protein obtained by purification and the polypeptide obtained by a synthetic method and the blebbistatin thereof, and an anti-NMHC II-A protein and anti-polypeptide antibody have inhibition activity on the PRRS virus infected cell, and can be developed into the drugs for preventing and treating the PRRS virus infection.

A monoclonal antibody B for the white spot virus receptor of prawn is prepared from the hybrid tumor cell (CCTCC-C200418) through conventional culture for 2-3 days to secrete a lot of said monoclonal antibody B. It can be used for preventing and treating whit spot of prawn.

The invention discloses a portunus trituberculatus reovirus receptor, a screening method and application thereof. The portunus trituberculatus reovirus receptor is characterized by being microtubulin. The screening method comprises the following steps: anatomizing healthy trituberculatus on ice, taking branchiae and adding the branchiae to a membrane protein extracting liquid, homogenizing, and performing resuspension on sediments obtained through centrifugation by the membrane protein extracting liquid so as to obtain a branchia membrane protein extracting liquid of portunus trituberculatus; performing separation on the membrane protein by using 8% SDS-PAGE and electrotransferring the membrane protein to a PVDF (polyvinylidene fluoride) membrane, performing overnight incubation by low-fat milk under 4 DEG C, washing the incubated membrane for three times, incubating the washed membrane for an hour by SCRV virus under room temperature, washing the incubated membrane for three times again, incubating the washed membrane by chicken antibody SCRV under room temperature for two hours, washing the incubated membrane for three times, incubating the washed membrane by a goat-anti-chicken second antibody in HRP coupling under room temperature for an hour, washing the incubated membrane for four times, performing color development by OPD so as to obtain a protein band, namely the SCRV receptor. The portunus trituberculatus reovirus receptor has the advantages that a receptor blocking agent has inhibitory activity to SCRV infection cells, and a medicine for preventing and treating SCRV infection can be developed.

The invention discloses an optimized target object capturing system based on a bacterial cell surface display system, namely, the optimized target object capturing system comprises the following steps: inserting a segment of coding genes of adaptor protein between a virus capsid protein coding gene and a coding gene inaQn which is responsible for transmembrane, transfer and anchoring and is in an N-terminal structure domain of ice-nucleation protein, and establishing recombinant plasmid of inducible surface display virus capsid protein after verifying; transforming host bacteria, thus obtaining an updated bacterial cell surface display system of capsid protein; displaying virus capsid protein on the surface of escherichia coli cells through inducible expression, thus obtaining an optimized virus receptor capturing system. Compared with a traditional virus receptor purification and analysis method, the bacterial cell surface display system has the advantages that the cost of a reagent is low, the operation is simple, the experimental period is short, requirements on experimental equipment are low, a virus receptor can be easily separated, background interference is reduced, and the like; an updated virus receptor capturing system lays a solid foundation for efficiently discovering new virus receptors, and meanwhile, a new thought for protein purification and concentration is also provided.

The invention relates to a zinc gluconate sugar tablet preparation and a preparation method thereof. The sugar tablet comprises the following components by mass: 93.24-160 parts of zinc gluconate and pharmaceutic excipients such as 1460-2500 parts of white sugar, 2910-5000 parts of maltose syrup or glucose syrup, 30-52 parts of glycine, 438-750 parts of purified water and 30-52 parts of fruit flavoring agents. The preparation is prepared by dissolving sugar at high temperature, boiling sugar under vacuum, etc. The form of the preparation is semi-transparent hard sugar tablet and the preparation is the buccal tablet. The sugar tablet is dissolved in the mouth, so that the zinc ions can permeate the nose, throat and susceptible tissues in the nasal sinus to be combined with the influenza virus receptor to prevent the influenza virus from further spreading among the cells so as to achieve the aims of treating cold and alleviating cold symptoms.

The invention mainly relates to an affinity peptide capable of being combined with hog cholera virus E2 protein and application of the affinity peptide. The sequence of the affinity peptide is HRKWKSKWK(P7). The affinity peptide has the advantages that a bovine viral diarrhea virus E2 protein crystal structure is used as the template, homologous modeling is performed to obtain the three-dimensional structure of hog cholera virus E2 protein, the peptide sequence with high score is obtained by the aid of the virtual molecular docking technology, and the obtained peptide sequence is P7; ELISA andSPR tests are used to identify the interaction affinity and specificity between the artificially-synthesized P7 sequence and the E2 protein, and the result shows that the P7 and the E2 can be combined in a high affinity and specificity manner; the qRT-PCR and IPMA tests are used to verify the virus infection inhibiting activity of the P7 sequence, and the result shows that the P7 sequence has good activity in hog cholera virus infection PK-15 cell inhibition; the affinity peptide can provide a reliable theoretical basis and new thought for the further research of virus receptor and antiviraldrug design.

To provide peptides having high affinity for hemagglutinin and peptides having high inhibitory activity against influenza virus infection, as well as pharmaceutical compositions containing the peptides, the polypeptides having any one of SEQ ID NOs: 2 to 7, 9 to 10, and 12 to 18 are obtained by introducing mutation into a peptide having the sequence of ARLSPTMVHPNGAQP (peptide A-1: SEQ ID NO: 1) and screening for peptides having higher affinity for hemagglutinin. Further, the inhibitory activity of the peptide of SEQ ID NO: 3 against influenza virus infection can be enhanced by truncating SEQ ID NO: 3 in its C-terminus region with leaving ARLPR (SEQ ID NO: 44) or ARLP (SEQ ID NO: 52). In addition, an influenza virus-infection inhibitor and an influenza preventive / therapeutic agent can be prepared by formulating these influenza virus receptor-binding peptides.

A method for combined detection of virus neutralizing antibodies and non-neutralizing antibodies, a detection card and its application, which detects neutralizing antibodies through the principle of virus receptor binding protein sandwich method, which is to set virus receptor binding proteins in advance and block neutralization The complex formed by the antibody and its ligand-binding protein captures the non-neutralizing antibody targeting the receptor protein in advance to ensure the specificity of the neutralizing antibody detected by the sandwich method. The invention solves the problems of low sensitivity, poor specificity and inability to distinguish neutralizing antibodies from non-neutralizing antibodies in the prior art, and provides a simple, rapid, highly sensitive and specific virus-neutralizing antibody and non-neutralizing antibody Neutralizing antibody joint detection method, detection card and application thereof.

The invention provides a fusion protein and application thereof. The fusion protein comprises nuclease, a virus antibody or a virus receptor. The fusion protein for preventing and treating viral infectious diseases is faster and easier to develop than vaccines, and has higher safety and effectiveness. The fusion protein can be popularized and applied to prevention and treatment of various virus infectious diseases.

Enveloped virus vectors are described which comprise a cellular virus receptor protein and which are capable of fusing with a cell which comprises a viral envelope protein to which the cellular virus receptor protein is cognate. Enveloped virus vectors comprising a plurality of cellular virus receptor proteins are also described. Methods for making the enveloped virus vectors are described, as are methods of using the enveloped virus vectors. The invention further relates to a lipoparticle comprising a membrane spanning protein, and the lipoparticle can be attached to a sensor surface. The invention relates to methods of producing and using the lipoparticle to, inter alia, assess protein binding interactions.

The invention belongs to the technical field of biological medicines, and particularly relates to a virus receptor protein for diagnosing leucoderma and application thereof. The invention discloses application of a molecular marker in preparation of a diagnostic kit for diagnosing leucoderma. The molecular marker is human skin melanocyte HSV-1 receptor protein. The human skin melanocyte HSV-1 receptor protein is determined by using a western blot method to carry out semi-quantitative analysis and predict whether the protein level is reduced or not. Experiments prove that after HSV-1 infects human melanocytes, expression of melanin synthesis related protein and a melanin synthesis function are inhibited by up-regulating VN1R5, so that leucoderma is caused. The process of the human skin melanocyte HSV-1 receptor protein is not complex, the detection result can be obtained by using a microplate reader, and the kit is mature in manufacturing means, easy to purchase and capable of being popularized in clinical application. It is found in the early stage that the reduced human skin melanocyte HSV-1 receptor protein level is beneficial to diagnosis of leucoderma, guidance of next treatment is facilitated, and the risk of disease deterioration of leucoderma patients is reduced.